– common in racehorses and sport horses
– overload due to hyperextension of the fetlock during the stance phase
(Genovese et al. 1990)
– temporary cessation of sports operations for 9 to 15 months
– possibly permanent cessation in case of recurrence
– repair according to the fibrositis process
– tissue obtained that is functionally deficient compared to the initial tissue
(Crevier-Denoix et al. 1997)
– tendon generally stiffer than initially
– predisposes to the creation of a new lesion above or below
of the initial lesion = recurrence
– originate from regenerative medicine
– aim to obtain a fabric very similar to the original fabric
– stimulus provided by PRP, stem cells or other substances
– numerous treatments
– some relatively empirical
– scientific validation:
– between 3 and 10 days after the accident
– choice of treatments to be carried out and convalescence
– to give a prediction
– assistance with monitoring and changing activity levels
– anti-inflammatory treatment as soon as it appears
- ice
– natural enlargement of the lesion during the first two weeks
– Proper immobilization during the first 10 days significantly limited this increase in lesion size (David et al. 2011)
– Robert-Jones dressing at a minimum, or even with a plaster cast, particularly if the fetlock has descended – splint limiting hyperextension of the fetlock (Equistride)
– fitting with a covered clamp and narrow sponges:
– inverted shoeing or shoeing with a narrow clamp and enlarged sponges:
– shoe both front hooves or both hind hooves with the same shoe
– 75 % of horses put out to pasture show a relapse (Gillis 1997)
– 50 % of horses receiving controlled convalescence develop a recurrence following superficial digital flexor tendonitis in steeplechase horses (Dyson 1994, OMeara 2010)
– well-defined protocol for managing tendinitis of the superficial digital flexor tendon in thoroughbreds (Godwin et al. 2012) – Thoroughbred: 11 months
– walker: 9 months?
– sport horse: 9 months?
– reducing this period increases the risk of relapse
(PRP = platelet-rich plasma)
– blood = several cell lines diluted in blood plasma
– Platelets: numerous growth factors that aid in the healing of various tissues
– centrifugation techniques
– platelet-rich plasma
– In vitro:
– In vivo:
– Clinical study:
• Summary : TVALIDATED TECHNIQUE
– cells capable of differentiating into different cell lineages:
– in horses, studies are mainly carried out on stem cells of mesenchymal origin: • bone marrow
– adipose tissue: appear to differentiate less well than cells from bone marrow (Toupadakis et al. 2007, Im et al. 2005, Vidal et al. 2007)
– few studies on the umbilical cord (Guest et al. 2010, Bi et al. 2007)
– more knowledge of bone marrow
– stem cells injected into sections of tendon
– survive, proliferate and migrate into the matrix to express several extracellular matrix genes (Stewart et al. 2009, Richardson et al. 2007)
– survival in the tendon for up to four months after implantation (Guest et al. 2008)
– tendinitis experimentally induced with collagenases
– significant improvements in tendon healing (Schnabel et al. 2009, Nixon et al. 2008) for bone marrow and adipose tissue
– 141 horses treated with follow-up for 113 horses
– Recurrence rate: 27.4% (%)
– 25.7 % for steeplechase horses (105 horses)
– 50 % for flat racing horses (8 horses)
– significantly lower than with conservative treatment alone
– no relationship with age, discipline, number of stem cells injected, or time of implantation after the accident
– bone marrow sampling
– injection of the prepared stem cells into the lesion
• summary : VALIDATED TECHNIQUE
– bone marrow:
cellular (but only from 0.01 % to 0.01 %)
– on the sternum
– on the ilium (pelvis)
– bone marrow concentrate
– contains up to 15 % stem cells (Nixon, 2010)
– PRP and bone marrow concentrate
– Tendinitis and desmitis of the superficial flexor tendon of the finger
and the suspensory ligament of the fetlock
– 13 sport horses
– controlled convalescence
– 85% of horses returned to competition (Torricelli et al. 2011)
– culturing blood on syringes containing glass beads marketed by the companies Orthokine and Arthrex
– IRAP-enriched serum: anti-inflammatory properties, used for the treatment of numerous joint problems
– not recommended for the treatment of tendinitis
– studies are underway to verify its potential effectiveness
– adverse effects on tendon repair in the medium term (Bosch et al. 2007)
- immobilization
– convalescence
– some have no proven effectiveness
By Dr. Matthieu COUSTY, ECVS Diplomate
Specialist in equine surgery
Any use of this document for commercial purposes is not permitted. Any partial or complete reproduction Total is not allowed.